Abstract:The rise of drug resistance has become a global crisis, with >1 million deaths due to resistant bacterial infections each year. Pseudomonas aeruginosa , in particular, remains a serious problem with limited solutions due to complex resistance mechanisms that now lead to more than 32,000 multidrug-resistant (MDR) infections and over 2000 deaths in the U.S. annually. While the emergence of resistant bacteria has become ominously common, identification of useful new drug classes has been limited over the past over 40 years. We found that a potential novel therapeutic, the peptide-mimetic TM5, is effective at killing P. aeruginosa and displays sufficiently low toxicity in mammalian cells to allow for use in treatment of infections. Interestingly, TM5 kills P. aeruginosa more rapidly than traditional antibiotics, within 30–60 min in vitro, and is effective against a range of clinical isolates, including extensively drug resistant strains. In vivo, TM5 significantly reduced bacterial load in the lungs within 24 h compared to untreated mice and demonstrated few adverse effects. Taken together, these observations suggest that TM5 shows promise as an alternative therapy for MDR P. aeruginosa respiratory infections.

Author Correction: Peptide-mimetic treatment of Pseudomonas aeruginosa in a mouse model of respiratory infection

Author Correction: Mechanosensing through immunoreceptors

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Peptide-mimetic treatment of Pseudomonas aeruginosa in a mouse model of respiratory infection

Corrigendum: The Capsule Depolymerase Dpo48 Rescues Galleria mellonella and Mice From Acinetobacter baumannii Systemic Infections

Corrigendum: A Systematic Study of the Stability, Safety, and Efficacy of the de novo Designed Antimicrobial Peptide PepD2 and Its Modified Derivatives Against Acinetobacter baumannii

Author Correction: Autophagy restricts Mycobacterium tuberculosis during acute infection in mice

Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer's Disease. Biomedicines 2022, 10, 985

Erratum for Poonawala et al., "Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis"

Correction: Novel aerosol treatment of airway hyper-reactivity and inflammation in a murine model of asthma with a soluble epoxide hydrolase inhibitor

Correction: He et al. Intranasal Administration of Agomir-let-7i Improves Cognitive Function in Mice with Traumatic Brain Injury. Cells 2022, 11, 1348

Correction: Tobramycin-mediated self-assembly of DNA nanostructures for targeted treatment of Pseudomonas aeruginosa -infected lung inflammation

Correction to: Human antimicrobial peptide LL-37 contributes to Alzheimer's disease progression

Author Correction: Mucosal vaccine-induced cross-reactive CD8 + T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection

Author Correction: C/EBPβ Regulates Delta-Secretase Expression and Mediates Pathogenesis in Mouse Models of Alzheimer’s Disease

Corrigendum: Characterising an Alternative Murine Model of Diabetic Cardiomyopathy

Author Correction: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

Corrigendum: Chlamydia pneumoniae CdsL regulates CdsN ATPase activity, and disruption with a peptide mimetic prevents bacterial invasion

Author Correction: Molecular insights and antibody response to Dr20/22 in dogs naturally infected with Dirofilaria repens

Author Correction: Generation of a lethal mouse model expressing human ACE2 and TMPRSS2 for SARS-CoV-2 infection and pathogenesis

Correction for Hu et al., "Mast Cell-Induced Lung Injury in Mice Infected with H5N1 Influenza Virus"